The Mycoplasma Testing Market is positioned for strong growth as pharmaceutical manufacturers increase investments in microbiological quality control. Market Research Future estimates that the market will expand from USD 1.35 billion in 2026 to USD 3.52 billion by 2035, with a CAGR of 10.20%.
The shift from traditional culture testing toward rapid molecular methods is one of the most significant developments in the industry. PCR-based assays can provide faster contamination screening, helping manufacturers reduce delays in production and quality-control workflows. Digital PCR is also attracting interest for highly sensitive applications.
Cell-line quality control currently represents the leading application, while gene and cell therapy manufacturing is expected to grow rapidly. The expansion of advanced therapy pipelines is creating demand for repeated testing throughout cell banking, development, manufacturing, and final product release.
North America held approximately 43.10% of market revenue in 2025, while Europe accounted for around 27.80%. Asia-Pacific is expected to expand at a 16.50% CAGR as pharmaceutical manufacturing capacity increases and companies invest in local quality-control laboratories.
The future of the market will increasingly involve automated, connected, and rapid testing systems. AI-supported contamination analytics, multiplex assays, contract testing services, and point-of-manufacturing molecular platforms could broaden the role of mycoplasma testing from routine compliance toward a more integrated part of modern biopharmaceutical quality management.
Dive into related studies for a broader industry perspective:
Chronic Lower Back Pain Treatment Market Volume
Chronic Lower Back Pain Treatment Market Forecast
Chronic Lower Back Pain Treatment Market Outlook